Director Changes at Woodford Patient Capital Trust

Steven Harris, who founded a firm that Woodford invested in will step down as non-executive director, to be replaced by Ruffer co-founder Jane Tufnell

James Gard 2 September, 2019 | 9:57AM

Exit sign

Woodford Patient Capital Trust (WPCT), the closed-end fund run by under-fire manager Neil Woodford, has announced changes to its board.

Steven Harris, the founder of pet hair allergy firm Circassia Pharmaceuticals (CIR), is to step down as a non-executive director at the end of this month. Woodford invested a substantial stake in Circassia when he worked at Invesco and also when he set up Woodford Investment Management in 2014. According to Morningstar data, the trust no longer holds a stake in Circassia, but Woodford Equity Income held 0.55% of its portfolio in the firm (as at end of April, 2019). Invesco also holds stakes in Circassia via open-ended and closed-end funds.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
Circassia Pharmaceuticals PLC25.00 GBX5.04
Woodford Patient Capital Trust25.65 GBX-8.39

About Author

James Gard  is content editor for Morningstar.co.uk

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2020 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies